Healthcare research from Johnson & Johnson, page 8
A filtered view. Show the full list.
Refine
Listings
-
ArticleCurrent medical research and opinion
Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleCurrent medical research and opinion
Mortality in generalized myasthenia gravis among Medicare beneficiaries in the United States
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Public healthAdded
-
ArticleCurrent medical research and opinion
Disease burden among patients with generalized myasthenia gravis in the United States receiving standard of care therapy: the patient perspective
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleLeukemia & lymphoma
Projected population size by treatment line in diffuse large B-cell lymphoma in the United States, 2024-2028
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Public healthAdded
-
ArticleJournal of medical economics
Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Public healthAdded
-
Clinical trial reportJournal of medical economics
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleJournal of medical economics
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleJournal of medical economics
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Public healthAdded
-
Clinical trial reportJournal of medical economics
Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportExpert opinion on biological therapy
Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleFuture oncology (London, England)
Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleFuture oncology (London, England)
Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportHematology (Amsterdam, Netherlands)
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleBioanalysis
2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV))
Verified Author affiliations on the Europe PMC record name Bristol Myers Squibb, GSK, Johnson & Johnson. Affiliation source
-
ArticleBioanalysis
Affinity-maturation engineering via phage display to optimize anti-idiotype antibodies for neutralizing antibody assays
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
-
ArticleBioanalysis
Optimizing acid type and pH for dissociation of biotin-labeled drug from streptavidin-coated bead in BEAD ADA assays
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
-
ArticlemAbs
Systematic characterization of lysine glucuronidation in a bispecific antibody
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
-
ReviewmAbs
Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industry
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
-
ArticleHuman vaccines & immunotherapeutics
Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Expanding access and comprehensive care in the management of patients with inflammatory bowel disease with pharmacy services
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportThe British journal of dermatology
Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
Clinical trial reportJournal of Crohn's & colitis
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded
-
ArticleHealth affairs scholar
Patient perspectives on cost and quality measures in value-based cancer care
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Public healthAdded
-
ArticleInflammatory bowel diseases
Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
Clinical careAdded